{"id":"NCT02652130","sponsor":"Mesoblast, Inc.","briefTitle":"Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD","officialTitle":"Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-28","primaryCompletion":"2018-06-15","completion":"2018-06-15","firstPosted":"2016-01-11","resultsPosted":"2022-03-16","lastUpdate":"2022-03-16"},"enrollment":32,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Grade B Acute Graft Versus Host Disease","Grade C Acute Graft Versus Host Disease","Grade D Acute Graft Versus Host Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Remestemcel-L","otherNames":[]}],"arms":[{"label":"Safety population","type":"EXPERIMENTAL"}],"summary":"Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT), that have failed to respond to treatment with systemic corticosteroid therapy.","primaryOutcome":{"measure":"Overall Survival Rate Through Day 180","timeFrame":"From Baseline Day 1 in the Study MSB-GVHD001 up to Day 180 in Study MSB-GVHD002 (180 days)","effectByArm":[{"arm":"Remestemcel-L","deltaMin":68.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":20,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":32},"commonTop":[]}}